Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-leukemia/Lymphoma Immune Therapy

• Mazdak Ganjalikhani-Hakemi,
• Ling Xu,
• Andrey A. Zamyatnin,
• Andrey A. Zamyatnin,
• Andrey A. Zamyatnin,
• Andrey A. Zamyatnin,
• Alexandr V. Bazhin,
• Alexandr V. Bazhin

Affiliations

Mazdak Ganjalikhani-Hakemi

Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Ling Xu

Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China

Andrey A. Zamyatnin

Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russia

Andrey A. Zamyatnin

Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia

Andrey A. Zamyatnin

Department of Biotechnology, Sirius University of Science and Technology, Sochi, Russia

Andrey A. Zamyatnin

Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom

Alexandr V. Bazhin

Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, Germany

Alexandr V. Bazhin

German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany